View Item 

Show simple item record

Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer–specific death in patients receiving salvage radiation therapy following radical prostatectomy
dc.contributor.authorJackson, Williamen_US
dc.contributor.authorHamstra, Daniel A.en_US
dc.contributor.authorJohnson, Skyleren_US
dc.contributor.authorZhou, Jessicaen_US
dc.contributor.authorFoster, Benjaminen_US
dc.contributor.authorFoster, Coreyen_US
dc.contributor.authorLi, Darrenen_US
dc.contributor.authorSong, Yeohanen_US
dc.contributor.authorPalapattu, Ganesh S.en_US
dc.contributor.authorKunju, Lakshmi P.en_US
dc.contributor.authorMehra, Rohiten_US
dc.contributor.authorFeng, Felix Y.en_US
dc.date.accessioned2013-10-02T15:13:32Z
dc.date.available2014-10-06T19:17:43Zen_US
dc.date.issued2013-09en_US
dc.identifier.citationJackson, William; Hamstra, Daniel A.; Johnson, Skyler; Zhou, Jessica; Foster, Benjamin; Foster, Corey; Li, Darren; Song, Yeohan; Palapattu, Ganesh S.; Kunju, Lakshmi P.; Mehra, Rohit; Feng, Felix Y. (2013). "Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer–specific death in patients receiving salvage radiation therapy following radical prostatectomy." Cancer 119(18): 3287-3294. <http://hdl.handle.net/2027.42/100176>en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/100176
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherGleason Patternen_US
dc.subject.otherProstate Canceren_US
dc.subject.otherSalvage Radiation Therapyen_US
dc.subject.otherOutcomesen_US
dc.subject.otherPrognosisen_US
dc.titleGleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer–specific death in patients receiving salvage radiation therapy following radical prostatectomyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23821578en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/100176/1/cncr28215.pdf
dc.identifier.doi10.1002/cncr.28215en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceCooperberg MR, Hilton JF, Carroll PR. The CAPRA‐S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011; 117: 5039 – 5046.en_US
dc.identifier.citedreferenceRoehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long‐term results. J Urol. 2004; 172: 910 – 914.en_US
dc.identifier.citedreferenceHan M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long‐term biochemical disease‐free and cancer‐specific survival following anatomic radical retropubic prostatectomy. The 15‐year Johns Hopkins experience. Urol Clin North Am. 2001; 28: 555 – 565.en_US
dc.identifier.citedreferenceCotter SE, Chen MH, Moul JW, et al. Salvage radiation in men after prostate‐specific antigen failure and the risk of death. Cancer. 2011; 117: 3925 – 3932.en_US
dc.identifier.citedreferenceKatz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003; 21: 483 – 489.en_US
dc.identifier.citedreferenceGoenka A, Magsanoc JM, Pei X, et al. Long‐term outcomes after high‐dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys. 2012; 84: 112 – 118.en_US
dc.identifier.citedreferenceTrock BJ, Han M, Freedland SJ, et al. Prostate cancer‐specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299: 2760 – 2769.en_US
dc.identifier.citedreferenceStephenson AJ, Scardino PT, Kattan MW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25: 4153 – 4153.en_US
dc.identifier.citedreferenceHashine K, Yuasa A, Shinomori K, Shirato A, Ninomiya I, Teramoto N. Tertiary Gleason pattern 5 and oncological outcomes after radical prostatectomy. Jpn J Clin Oncol. 2011; 41: 571 – 576.en_US
dc.identifier.citedreferenceTrock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol. 2009; 182: 1364 – 1370.en_US
dc.identifier.citedreferenceStock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high‐grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int. 2009; 104: 1631 – 1636.en_US
dc.identifier.citedreferenceSabolch A, Feng FY, Daignault‐Newton S, et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose‐escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys. 2011; 81: e351 – e360.en_US
dc.identifier.citedreferenceVis AN, Roemeling S, Kranse R, Schroder FH, van der Kwast TH. Should we replace the Gleason score with the amount of high‐grade prostate cancer? Eur Urol. 2007; 51: 931 – 939.en_US
dc.identifier.citedreferenceNanda A, Chen MH, Renshaw AA, D'Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high‐risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys. 2009; 74: 1419 – 1423.en_US
dc.identifier.citedreferenceCheng L, Koch MO, Juliar BE, et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol. 2005; 23: 2911 – 2917.en_US
dc.identifier.citedreferenceSpiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse‐free survival with whole pelvic compared with prostate bed only for high‐risk patients. Int J Radiat Oncol Biol Phys. 2007; 69: 54 – 61.en_US
dc.identifier.citedreferenceShipley WU, Hunt D, Lukka HR, et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti‐androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2–3,N0 disease and elevated PSA levels. J Clin Oncol. 2011; 29: 1.en_US
dc.identifier.citedreferenceFine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496 – 509.en_US
dc.identifier.citedreferenceCharlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373 – 383.en_US
dc.identifier.citedreferenceD'Ambrosio DJ, Hanlon AL, Al‐Saleem T, et al. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 1082 – 1087.en_US
dc.identifier.citedreferenceShilkrut M, McLaughlin W, Merrick GS, et al. Interval to biochemical failure predicts clinical outcomes in patients with high‐risk prostate cancer treated by combined‐modality radiotherapy [published online ahead of print May 9, 2013 ]. Int J Radiat Oncol Biol Phys. doi: 10.1016/j.ijrobp.2013.03.028.en_US
dc.identifier.citedreferenceBuyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer‐specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70: 59 – 66.en_US
dc.identifier.citedreferenceFreedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer‐specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433 – 439.en_US
dc.identifier.citedreferenceJohnson S, Jackson W, Li D, et al. The interval to biochemical failure is prognostic for metastasis, prostate cancer‐specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013; 86: 554 – 561.en_US
dc.identifier.citedreferenceBenaim EA, Pace CM, Roehrborn CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol. 2002; 42: 12 – 17.en_US
dc.identifier.citedreferenceEpstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29: 1228 – 1242.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr28215.pdf
Size:
250.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.